Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists Academic Article uri icon

Overview

MeSH Major

  • Antiphospholipid Syndrome
  • Benzoates
  • Hydrazines
  • Lupus Erythematosus, Systemic
  • Pyrazoles
  • Receptors, Thrombopoietin
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • Thrombosis

abstract

  • Our results suggest that aPLs should be systematically screened before TPO-RA initiation in patients with SLE. With aPL positivity, alternative therapy should be discussed (if possible), especially in patients with definite APS or suboptimal adherence to anti-coagulation therapy.

publication date

  • August 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/rheumatology/key119

PubMed ID

  • 29757439

Additional Document Info

start page

  • 1432

end page

  • 1438

volume

  • 57

number

  • 8